CG Oncology (CGON) Total Liabilities (2023 - 2026)
CG Oncology's (CGON) quarterly Total Liabilities came in at $43.5 million in Q1 2026, up 85.64% YoY from $23.4 million in Q1 2025, and up 11.52% on a QoQ basis from $39.0 million in Q4 2025.
CG Oncology (CGON) Total Liabilities (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Total Liabilities data on file, last reported at $43.5 million in Q1 2026.
- Quarterly Total Liabilities rose 85.64% year-over-year to $43.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.5 million (up 85.64% YoY) and the FY2025 annual result came in at $39.0 million, up 82.03% from the prior year.
- Total Liabilities rose to $43.5 million in Q1 2026, from $39.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $43.5 million in Q1 2026 to a low of $10.2 million in Q1 2024.
- A 4-year average of $25.3 million and a median of $22.4 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2024 — Total Liabilities surged 47.61% — and 2025, when it jumped 169.22%.
- Tracing CGON's Total Liabilities over 4 years: stood at $14.5 million in 2023, then surged by 47.61% to $21.4 million in 2024, then soared by 82.03% to $39.0 million in 2025, then increased by 11.52% to $43.5 million in 2026.
- The last three Total Liabilities figures came in at $43.5 million (Q1 2026), $39.0 million (Q4 2025), and $42.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 56.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.54 Mn |
| Mar 31, 2026 | 43.48 Mn |
| Dec 31, 2025 | 38.99 Mn |
| Sep 30, 2025 | 42.27 Mn |
| Jun 30, 2025 | 31.09 Mn |
| Mar 31, 2025 | 23.42 Mn |
| Dec 31, 2024 | 21.42 Mn |
| Sep 30, 2024 | 15.70 Mn |
| Jun 30, 2024 | 11.97 Mn |
| Mar 31, 2024 | 10.17 Mn |
| Dec 31, 2023 | 14.51 Mn |